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Abstract. The growing demand of personalized medicine
marked the transition from an empirical medicine to a
molecular one, aimed at predicting safer and more effective
medical treatment for every patient, while minimizing
adverse effects. This passage has emphasized the importance
of biomarker discovery studies, and has led sample
availability to assume a crucial role in biomedical research.
Accordingly, a great interest in Biological Bank science has
grown concomitantly. In biobanks, biological material and
its accompanying data are collected, handled and stored in
accordance with standard operating procedures (SOPs) and
existing legislation. Sample quality is ensured by adherence
to SOPs and sample whole life-cycle can be recorded by
innovative tracking systems employing information
technology (IT) tools for monitoring storage conditions and
characterization of vast amount of data. All the above will
ensure proper sample exchangeability among research
facilities and will represent the starting point of all future
personalized medicine-based clinical trials.
With the advent of “omic” sciences, the significance and
applications of precision medicine could allow the design of
personalized health therapy regimens, based on individual
biological variability. To this purpose, it is mandatory to
identify the factors that predispose an individual to disease,
recognize the features of progression, and predict patient
response to treatment. Under this light, the availability of a
large number of standardized biological specimens has
assumed a crucial role in the field of biomedical research,
especially since many research activities are seriously
invalidated by the different methodological approaches
employed during sample handling and storage.
In the present review we consider certain issues related to
proper management of biospecimens in order to enable
biological resource Centres to establish shared searchable
collections of samples, that might pose the basis for future
personalized medicine-based clinical trials.
A systematic literature review was performed by searching
PubMed-Medline, Scopus and Web of Science. Inclusion
criteria regarded relevant research studies, among those
published in English. For the selection of the search terms we
referred to previous literature reviews and the key words of
leading papers on the topic of biomarker discovery and
biobanking as provided by ISBER guidelines (www.isber.org.
Last access to databases: July 2015.
Personalized Therapy, Lessons 
from Molecular Medicine
In recent decades we have witnessed a substantial change in
our approach to medicine. A great shift has been witnessed,
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going from a global approach, that considers the various
clinical entities at the same level, to a growing demand for
providing personalized medicine that, besides predicting
which medical treatments will be safe and effective for a given
patient, will also provide indications for patients to whom
treatment could be useless, or worst, harmful. This new
“vision” has given birth to a deeper research in the “omics”
field (proteomics, peptidomics, lipidomics, metabolomics,
trascriptomics) in order to identify more promising tools for
risk assessment, identification and validation of new diagnostic
biomarkers, drug targets or improvement of tailored treatment
strategies (Figure 1) (1). This passage from an empirical
medicine to a molecular one has, therefore, emphasized the
importance of biomarker discovery.
Furthermore, understanding the genetic, cellular and
molecular basis of many diseases has greatly improved thanks
to the introduction of new biotechnologies, that promote the
implementation of biomarker discovery studies designed to
identify new biomarkers that predict, in a personalized way,
the evolution of the disease, the lack of response to a given
drug treatment, or the possible occurrence of side-effects. In
addition, the integration of computerized data derived from
studies of biomarker discovery has helped defining new
algorithms for the definition of risk to be applied in a
customized clinical approach that, ultimately, would allow the
prompt application of treatment protocols optimized for each
individual patient and an economically more rationale use of
drugs (2).
In order for biomarkers to be clinically approved, they
should be confirmed and validated on a large number of
specimens and should be reproducible, specific, and sensitive
(3). Once validated, they can provide valuable information
about screening, follow-up, and prediction of response to
treatment (4). In an accurate analysis of the major pitfalls in
the translation from biomarker discovery to clinical utility,
Drucker has identified three areas of potential intervention,
the possibility to make different selections before initiating
the discovery phase, the adoption of biomarker
characterisation/validation strategies, and the robustness of
analysis techniques used in clinical trials (2).
Biological Banks and Biospecimen Science
Given the potential applications of biomarker discovery
studies to the pharmaceutical, biotechnological and
bioinformatics fields, one can understand the great interest
of biomedical research in Biological Banks. Indeed,
technological advances in various fields of human research
has allowed for designing research projects involving a large
amount of biological samples from high numbers of well-
stratified individuals affected, carriers, or predisposed to
genetic or environmental diseases, or from those exhibiting
variable response to drugs, possibly in comparison with
matched control groups. Consequently, sample availability
has assumed a crucial role in the field of biomedical
research, at the point that many research activities are
seriously invalidated by the heterogeneous quality of the
human specimens used (5, 6). At present, in fact, the
heterogeneity in the quality of collected biomaterials is often
significant, at a point that many researchers feel that it may
contribute to irreproducible results, impeding the
development of more effective therapeutics and diagnostics
(7, 8). This issue was extensively discussed at the 2nd
Annual Biospecimen Research Symposium organized by the
Biorepository and Biospecimen Research Branch (BBRR,
formerly Office of Biorepository and Biospecimen Research)
of the Cancer Diagnosis Program at the National Institutes
of Health, USA on March 2009, during which the results of
a survey carried-out among researchers were reported,
showing that a substantial proportion of them feels that
sample quantity/quality was defective, thus limiting their
scope of work (Figure 2) (http://biospecimens.cancer.gov/
meeting/brnsymposium/2009/).
In this context, Biological Banks, defined in the Oviedo
Convention as "operational units that provide a service for
the storage and management of biological material and
associated clinical data, in accordance with a good laboratory
practice, privacy law and ethics guidelines", are an important
font of resources even after many years of collection. These
facilities, also thanks to the implementation of standard
operating procedures (SOPs), harmonization of the available
information, together with the development of processes of
data integration, are well-suited to the growing demand for
biological samples homogeneous for pathology, clinical
features and collection and storage procedures, to be
included in research protocols. 
Among the goals pursued by a Biological Bank, the
following should be highlighted:
• To encourage scientific research for the identification of
pathophysiological mechanisms.
• To provide an adequate number of biological samples for
studies of biomarker discovery for the identification of new
predictive, diagnostic and/or prognostic biomarkers,
potentially transferable to clinical applications, up to
innovative treatments such as "targeted therapy".
Accordingly, for the constitution of an efficient Biobank
it is not only necessary that the biological material is
collected, handled and stored in a technically appropriate
manner, but that samples are also accompanied by a
complete clinical documentation, archived through a
computer support that allows for complete recovery of data
in accordance with the protection of existing legislation on
privacy of the donor subject. Such a tracking system
translates into an immense value being able to allow data
exchange process with consequent exponential beneficial
effects for research (with a significant improvement in inter-
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institute sample exchangeability), hospitals, industries, and,
by extension, citizen health care. Biobanks are, thus,
important resources whose value resides not only in the
stored material, but also in the associated information that
are made accessible for scientific investigation. Collecting
samples and data, and hence storing them, allows not only
to gain a large collection of cases for future studies, but also
to follow-up the evolution of a given disease. 
One example of clinical application of personalized
medicine comes from the management of cancer patients,
that represents a key area of care in Europe. Cancer, in fact,
is a major cause of morbidity and mortality worldwide and,
according to the latest estimates, the incidence and
prevalence of malignant tumors are increasing in both sexes,
boosted by the increasing aging population. Over the past
two decades, the progress made with the introduction of new
therapeutic approaches, better organization of services,
increase investment in support services, and improvement of
screening services and prevention, has resulted in an increase
in survival and a reduction in mortality from cancer, and in
increased costs of management for cancer patients. Indeed,
it now appears evident that conventional therapeutic
approaches based on the choice of chemotherapy on the basis
of histopathological evaluation of the tumor is out-dated, in
an era in which personalized oncology is based on a
pharmacogenomic evaluation and on the way neoplastic cells
respond to targeted chemotherapeutics (Figure 3) (9). Thus,
research has focused on the cellular and molecular
mechanisms of tumor development, growth and metastasis,
which has led to the identification of new cancer-specific
molecular targets (10-12), generally consisting of single
genetic mutations, epigenetic modifications, or gene
amplifications/translocations (13). The understanding over
the molecular basis of cancer has allowed for significant
improvement in assessing the etiopathogenetic mechanisms,
identifying new biomarkers as determinants of outcome
response rates, ensuring survival and safety (14, 15),
predicting patient's failure to respond to drug treatment, or
identifying and minimizing the occurrence of side-effects,
through integration of the acquired genetic knowledge and
knowledge on drug effects (reviewed in 9, 16, 17). Thus, it
should be highly valuable to understand how gene mutations
generate different clinical features with different behaviours
concerning both their aggressiveness and response to
treatment, in order to set-up the best tailored-therapy for
each patient (18). Indeed, this will allow identification not
only of patients who may benefit for a targeted-treatment,
but also of patients for whom a pharmacogenomic-based
therapy might be detrimental (Figure 3).
In this light, the availability of a Biobank with SOPs
diversified depending on the nature of test samples, will
allow execution of specific studies for identifying molecular
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Figure 1. From gene profiling to tailored therapy. Gene profiling allows patient pharmacogenomic evaluation and disease-specific molecular
biomarker identification. A prognostic biomarker will help develop new therapy approaches  later employed in populations of patients who are
likely to respond to these treatments, and for whom the specific biomarker will have a predictive role. 
markers and genetic profiles for certain chronic disorders,
e.g. cancer, that will help draw guidelines aimed at
optimizing the risk/benefit of chemotherapy in cancer
patients, with the ultimate goal of improving clinical
outcomes and quality of life (QoL). Of particular note are
the surveys conducted over the last three years by our
working group, in order to: (i) identify biomolecular patterns
that correlate to cancer development, to predictability of
response of specific therapeutic approaches, as well as to the
possibility of adverse events during treatment, in order to
enhance both prognosis and QoL of patients (19-24); (ii)
identify candidate genes predisposing to the onset of
migraine, which could allow not only a molecular
classification of various clinical forms of this highly
disabling neurological disorder, but also a tailored-treatment
and/or prophylactic approach (25, 26); (iii) investigate novel
genetic variants involved in the pathophysiology of coronary
microvascular dysfunction and ischemic heart disease, in
order to design a customized clinical approach capable of
improving patients’ functional recovery (27, 28). 
Sample Quality, a Mandatory Constraint
From the time of collection to storage and future analysis,
the sample undergoes three major stages of processing: pre-
analytical, analytical, and post-analytical. Unfortunately, the
lack of adherence to guidelines and to standardized
procedures in each of these equally important phases, has
often rendered efforts to obtain reliable results in sample
comparative analysis, useless and only few clinical
biomarkers have proven useful and have been validated for
routine clinical practice (29).
Moreover, using the right technology able to identify the
proper resource for interpretation of the results is often
complex, the current availability of biological material is
insufficient and uneven among the various Research Centres,
the existing storage areas are not always correctly handled,
for organizational and/or financial reasons, and they often
lack systems for control and monitoring. Inappropriate
processing, handling and storage of blood samples may
significantly affect the reliability of the material. 
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Figure 2. Difficulties and consequences in acquiring the quantity of quality samples needed. Variability of collection, processing, storage, and
annotation of the majority of human bio-specimens available for research, have been included in a survey directed to researchers. A lack of ease in
acquiring the quantity of “quality” biospecimens needed emerged, as well as the  the fact that many investigators question their data due to the
shortage of quality samples used, which, thus, limits the scope of their work. Modified from Compton CC. The Cancer Human Biobank (CaHuB):
(Advancing the Vision of Personalised Medicine. Available at: http://biospecimens.cancer.gov/ meeting/brnsymposium/2009/).
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Figure 3. Clinical outcome following stratification on the basis of presence of a predictive biomarker. The presence of a given biomarker will generate
different clinical features with different behaviours concerning tumor aggressiveness and response to treatment that allow to set-up the best tailored-
therapy for each patient. This pharmacogenomic-based approach will identify patients which may benefit for a targeted-treatment (dashed column),
and those for whom it might be detrimental (filled column). For the latter, standard therapy (empty column) might still represent the best choice.
Figure 4. Radio-frequency identification (RFID) technology to track sample storage conditions. RFID system employs a contactless passive
transmission and the electronic information is written on a portable remote writer/reader device that allows multiple and contemporary readings of
RFID supports. A time report is provided for every operation performed, which is recorded in session logs (operator identification, door
opening/closing, rack insertion/extraction, sample insertion/retrieval) by means of a hand-held RFID reader. All data will be transmitted to
Laboratory Information System (LIS) and will become part of the sample stored record (Modified from 54). 
The concept of "sample quality", already raised in several
reports, could be rendered as "the ideal sample for a given
purpose", and could thus be translated into “sample suitability”,
and should last for the sample entire life-span. However, in a
Biobank, once the "goodness" of a sample is ascertained, its
“quality” depends almost entirely on pre-analytical variables
related to the method of preservation of the sample itself. In
particular, it is widely dependent on storage conditions and on
the stability of freeze/thaw cycles (30).
With regard to storage conditions, a sample can be
considered stable if not altered by thermal, mechanical or
chemical stress induced during freezing and thawing, stabilizer
cytotoxicity, crystallization damage, repeated freeze/thaw
damage and osmotic lysis. Indeed, proper storage ensures that
sample degradation is minimized, in order to avoid that
information inherent to samples can be seriously compromised
by unsuitable preservation practices. It is estimated that about
10% frozen samples are unsuitable, due to extra-analytical
phases, lack of standardized procedures, and specimen
acquisition, handling and storage (31).
Temperature control during sample processing is essential
and determines the suitability of the sample itself (32-34).
Ideally, the storage of many aliquots of small volumes (35)
should ensure a resource for a wide range of future scientific
researches, and a temperature of -80˚C should be adopted in
order to allow for soluble biomarkers to remain intact (4, 33,
36, 37). Alternatively, storage in liquid nitrogen may be
required for certain very easily-degradable biomarkers (38, 39).
Different storage conditions are required depending on the type
of sample used and even of the biomarker under investigation
(40). For instance, while isolated RNA must be stored at -80˚C
(41, 42), isolated DNA, whose recovery significantly decreases
at RT, can be stored at 4˚C for weeks, and kept at -80˚C for
several years (43, 44). Conversely, live cells are stable at RT
for up to 48 h but should be either cultured or cryopreserved
in liquid nitrogen (45). However, the literature extensively
reports that optimal storage conditions are different depending
on the cell type and the preservation medium used (for review
see 46). Furthermore, storage of serum at -20˚C is unsuitable
for the vast majority of biomarker-based researches (34) and
time-dependent decay has also been reported for many bodily
fluids (38, 47, 48). Finally, some processing conditions
negatively affect the sample status, such as out of range
temperatures, multiple freeze-thaw cycles (30, 34), which may
even occur during the time intervals between processing steps.
The Biospecimen Reporting for the Improved Study Quality
(BRISQ), has released recommendations for reporting data
elements of human biospecimens (solid tissues and bodily
fluids), expanding to the whole life-cycle of a sample (from
collection to analysis) aimed at harmonizing the methods to
trace information and facilitate effective inter- and intra-
laboratory specimen sharing/use. (49). The importance of
procedure setting-up and recording along the whole life cycle
of biological specimens, allows to track the history of the
sample itself and to detect, eventually, the evidence of decay
and to rapidly identify artefacts during downstream sample
assay (50, 51). 
ICT Tools in Biobanking
The technical-scientific interest in bio-repositories includes, of
course, more disciplines, concerning not only the health sector,
but also the high-tech ICT. In fact, medicine and biology have
the indispensable need to use IT tools for storage and
characterization of the vast amount of data that modern
biological research produces thanks to technological progress.
Following the recommendations published on the guidelines
of the National Institutes of Health BBRR (52) foreseeing the
need for more detailed information of samples used for
research activities, a turning point has been represented by the
development of the sample pre-analytical code (SPREC)
labeling system (50). This system consists of a 7-digit code,
in which each element corresponds to a punctual pre-analytical
variable and contains a string of letters (different for each type
of tissue) (53) that provides detailed information on all pre-
analytical procedures that a single stored specimen
encountered during its manipulation (53, 50). 
Many Information and Communication Technology (ICT)
tools have been proposed to offer comprehensive insight into
the specimen features and to trace the procedures it has
undergone. This is the case of system warehouses
infrastructures, that have been designed to better integrate
clinical and research data of samples stored in biological bank
facilities, combining clinical data and research results.
Examples of this technological tool are represented by the
SPRECware (54), the ONCO-i2b2 (55) and the p-BioSPRE
(p-medicine Biospecimen Search and Project Request Engine)
(56) platforms, which have been set-up to find clinical data
and all the information associated with pre-analytical encoding
related to patient’s sample through query tool interfaces and
to provide tools for biological specimens and related clinical
data exchange. 
A comprehensive guideline, Model Requirements for the
Management of Biological Repositories (BioReq), which,
among the ICT requirements aimed at identifying the
applicable tools to develop a Biobank information system, has
reported a flow chart presenting the biological sample lifecycle
processes from sample acquisition, through sample and data
management, to sample destruction and distribution (57). In
this light, a fine application of ICT to Biorepositories, is
provided by radio-frequency identification (RFID) (54) or
bluechiip® (58) technologies, which have been employed to
ameliorate the tracking of the whole biospecimen chain of
custody (54, 59-61). 
RFID is a technology that that does not require bar code
labelling, but uses communication via radio waves to
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exchange data between a reader (interrogator) and an
electronic tag attached to an object (label), for the purpose of
identification and tracking (54). The cryotag uses a
transmission contactless passive type and the electronic
information is copied on a portable remote writer/reader
device that allows multiple and contemporary readings of
RFID supports and can associate a time record to every
operation performed. Each operation concerning the insertion
or retrieval of samples is recorded in session logs (including
the identification of the operator and a sequence of operations,
which may consist of inserting and/or extracting a rack or a
single aliquot into/from a rack) by means of a hand-held RFID
reader (54) (Figure 4). All data will then be transmitted to LIS
and will become part of the sample stored record.
For its own features, RFID, radio waves, due to its low
sensitivity to dirt, wrinkling, solvents, temperatures (59, 60),
and pressure conditions (62), has proven an ideal tool to
track the life cycle of samples between the end of the pre-
analytical phase and the beginning of the analytical one, up
to long-term storage (54). The Multidisciplinary Inter-
institutional Biobank (BioBIM) of the IRCCS San Raffaele
Pisana in Rome, Italy, has reported a pilot experience by
collecting detailed reports encompassing the storage stages
of biosamples, integrating data in the existing Laboratory
Information System (LIS), and testing the durability of
information at low temperatures, which resulted stable over a
period of 5 years (Guadagni, F. Personal communication).
One important feature of this technology is represented by
the capability of RFID to read several transponders
simultaneously, recognizing each individual sample, to
contain kilobytes of data and to be potentially re-usable
several times, since the transponder can be written-over an
unlimited number of times. This, in addition to the
possibility to place RFID tags on the cryovials, or on the
wall of cryoplate/cryobox or, even, on the freezer door (63),
allows to build-up a significant cost-effective policy.
The bluechiip® technology, in turn, is a passive wireless
technology based on MEMS (micro electromechanical
systems) equipped with a bluechiip® button ID device
embedded into a Corning® 1.2-ml cryovial and the bluechiip®
Matchbox® reader (56). In a pilot study conducted by the
American Type Culture Collection (ATCC) to test bluechiip®
efficiency against standard 1-D bar-code labelling systems,
bluechiip® proved reliable when tested in extreme conditions
(i.e. freeze/thaw centrifuge, snap-freezing, frost, autoclaving,
microwave), in comparison to bar-code labels (56). 
An essential feature of these IT devices – RFID or
bluechiip® – is the possibility to implement solutions where
the “events” are tracked autonomously, i.e. there could be no
need of an explicit “reading” action performed by the involved
operator. This opportunity reduces dramatically the possibility
of human errors while simplifying the activities of operators
who can focus on proper handling of samples.
Concluding Remarks
Based on these considerations, the implementation of a
clinical database including clinical information of case
studies relevant to cancer patients, associated with a Biobank
able to collect biological samples from these individuals,
represents an essential tool for evidence-based studies, in
which the optimization of the SOPs and harmonization of the
available information, together with the development process
of data integration, could readily facilitate biomedical
research. Of course, the availability of systems for
monitoring storage conditions in bio-repositories, that ensure
proper sample exchangeability among research facilities, will
represent the starting point of future personalized medicine-
based clinical trials, and will be of outmost importance in the
evaluation of health needs of an increasing patient population
and for planning of interventions aimed at social welfare
prevention and improving the QoL of patients through the
standardization of differentiated treatment programs.
Additional advantages would be to better-define and develop
a set of clinical/ diagnostic algorithms enabling for more
accurate classification of the biological characteristics of
each patient, accompanied by information predictive of
clinical outcome and/or responsiveness to therapy.
Ultimately, this will translate into obvious repercussions on
the National Health Service and industry, with a consequent
improvement in public health. 
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